Sonoma Pharmaceuticals
SNOA
16 hedge funds and large institutions have $54.8K invested in Sonoma Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
33% more funds holding
Funds holding: 12 → 16 (+4)
0.01% less ownership
Funds ownership: 0.12% → 0.11% (-0.01%)
44% less capital invested
Capital invested by funds: $97.3K → $54.8K (-$42.5K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$37.2K |
| 2 |
JP Morgan Chase
New York
|
+$10.5K |
| 3 |
Millennium Management
New York
|
+$10.2K |
| 4 |
HF
HRT Financial
New York
|
+$8.88K |
| 5 |
Goldman Sachs
New York
|
+$3.23K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$29.7K |
| 2 |
Renaissance Technologies
New York
|
-$11K |
| 3 |
BlackRock
New York
|
-$198 |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$38 |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6 |
SNOA Hedge Fund Activity: Q4 2023 in Review
16 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q4 2023, worth a combined $54.8K — down 44% from $97.3K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new SNOA positions and 3 closed out — a net gain of 4 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $37.2K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $29.7K sold.
- 16 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q4 2023, up from 12 in Q3 2023.
- Funds reported $54.8K of Sonoma Pharmaceuticals stock for Q4 2023, down 44% quarter-over-quarter.
- 7 funds opened new Sonoma Pharmaceuticals positions in Q4 2023 and 3 closed out, a net change of +4 holders.
- The largest Sonoma Pharmaceuticals buyer in Q4 2023 was Citadel Advisors, an estimated $37.2K added.
- The largest Sonoma Pharmaceuticals seller in Q4 2023 was Two Sigma Securities, an estimated $29.7K sold.
Based on aggregated 13F filings for Q4 2023.